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Tumour-associated macrophages, TAMs, play a pivotal role in tumour growth and metastasis by promoting tumour angiogenesis.
Treatment with clodronate encapsulated in liposomes (clodrolip) efficiently depleted these phagocytic cells in the murine F9
teratocarcinoma and human A673 rhabdomyosarcoma mouse tumour models resulting in significant inhibition of tumour growth
ranging from 75 to 492%, depending on therapy and schedule. Tumour inhibition was accompanied by a drastic reduction in blood
vessel density in the tumour tissue. Vascular endothelial growth factor (VEGF) is one of the major inducers of tumour angiogenesis
and is also required for macrophage recruitment. The strongest effects were observed with the combination therapy of clodrolip and
a VEGF-neutralising antibody, whereas free clodronate was not significantly active. Immunohistologic evaluation of the tumours
showed significant depletion of F4/80
þ and MOMA-1
þ and a less pronounced depletion of CD11b
þ TAMs. Blood vessel staining
(CD31) and quantification of the vessels as well as TAMs and tumour-associated dendritic cells (TADCs) in the A673 model showed
reduction rates of 85 to 494%, even 9 days after the end of therapy. In addition, CD11c
þ TADCs, which have been shown to
potentially differentiate into endothelial-like cells upon stimulation by tumour released growth and differentiation factors, were
similarly reduced by clodrolip or antibody treatment. These results validate clodrolip therapy in combination with angiogenesis
inhibitors as a promising novel strategy for an indirect cancer therapy aimed at the haematopoietic precursor cells that stimulate
tumour growth and dissemination and as a tool to study the role of macrophages and dendritic cells in tumorigenesis.
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Solid tumours are not only composed of malignant cells, but are
complex organ-like structures comprising many cell types,
including a wide variety of migratory haematopoietic and resident
stromal cells (Pollard, 2004). The role of leucocyte infiltration into
solid tumours was noticed more than a decade ago. Migration of
these cell types into tumours has been interpreted as evidence for
an immunological response of the host against a growing tumour,
but more recently it became clear that tumours are largely
recognised as self and lack strong antigens. Instead, they appear
to have been selected to manipulate the host immune system to
prevent rejection and to use it to facilitate their own growth and
spread (Khong and Restifo, 2002; Ochsenbein, 2005). This led to
the proposal that haematopoietic cell infiltrates composed of
myeloid cells, neutrophils, dendritic cells (DCs), eosinophils, mast
cells, lymphocytes and macrophages have a causal role in
carcinogenesis. Clinical data collected from a wide range of solid
tumours underscore these findings given that high densities of
leucocytic infiltrations, most notably macrophages, correlate with
poor prognosis of the diseases (Chen et al, 2005; Joyce, 2005).
Tumour-associated macrophages (TAMs) produce a vast
number of factors that promote tumorigenesis. The most
prominent include basic fibroblast growth factor (bFGF), vascular
endothelial growth factor (VEGF), platelet-derived growth factor
(PDGF), transforming growth factor beta (TGFb), the angiopoie-
tins (Ang1 and Ang2), interleukins such as IL-1 and IL-8, tumour
necrosis factor-a (TNF-a), thymidine phosphorylase (TP), the
matrix metalloproteinases MMP-9 and MMP-2, nitric oxide (NO)
and chemokines (Pollard, 2004). The coordinated spatial and
temporal expression of these molecules results in proliferation and
migration of endothelial cells (ECs), remodelling of the extra-
cellular matrix and formation of stabilised blood vessels. Macro-
phages are perfectly apt to promote these processes, as their
monocytic precursors migrate to specific locations such as hypoxic
tumour tissues (Mantovani et al, 2004; Murdoch et al, 2004;
Pollard, 2004), where they differentiate and synthesise angiogenic
molecules. It is well established that tumours require angiogenesis
to grow beyond a size of a few millimetres. Angiogenesis has also
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sbeen found to be crucial for extensive tumour growth and
metastasis by providing oxygen and nutrients and removal of
waste products (Folkman, 2003). The VEGF family of growth
factors, consisting of structurally highly related proteins and their
corresponding receptors, play an essential role in angiogenic
processes in haematological malignancies and in solid tumours
(Podar and Anderson, 2005). Several therapeutic approaches
targeting VEGF or its receptors show good clinical results (Joyce,
2005; Vosseler et al, 2005). Furthermore, recent studies indicate
that vasculogenesis, mediated by the recruitment of bone-marrow-
derived vascular leucocytes, which simultaneously express both
endothelial and dendritic cell markers and differentiate into
endothelial-like cells, plays an important role in tumour angio-
genesis (Coukos et al, 2005). The crucial role macrophages play
in pathological lymphangiogenesis was documented in a recent
publication by Maruyama et al (2005), who provided evidence that
CD11b
þ macrophages are able to transdifferentiate into lymphatic
endothelial cell clusters that join existing lymph vessels in a mouse
corneal transplantation model.
Bisphosphonates are compounds used in the clinic to prevent
or inhibit the development of bone metastases or excessive bone
resorption and for the therapy of inflammatory diseases such as
rheumatoid arthritis and osteoarthritis (Rogers et al, 2000; Ross
et al, 2004). Recently, the use of bisphosphonates as antiangiogenic
agents has been found to suppress solid tumour growth and
metastases (Giraudo et al, 2004). With the encapsulation of the
bisphosphonate clodronate into liposomes (clodrolip), an efficient
reagent for the selective depletion of macrophages has been
developed and successfully applied in several immunological
studies (Seiler et al, 1997; Tyner et al, 2005). We therefore
investigated the possibility whether depletion of TAMs would
inhibit tumour angiogenesis and consequently tumour growth and
dissemination. Here, we show for the first time that clodronate-
liposome-mediated TAM depletion inhibits tumour growth,
presumably through blocking of tumour angiogenesis. In our
experiments, tumour-bearing mice were treated with clodrolip as
single therapy in comparison to free clodronate and in combina-
tion with anti-VEGF single chain fragment antibodies (Abs),
resulting in drastic tumour growth inhibition and exhaustion of
TAM and TADC cell populations.
MATERIALS AND METHODS
Cells and mice
Murine F9 teratocarcinoma (CRL-1720), human A673 rhabdomyo-
sarcoma (CRL-1598) were from American Type Culture Collection
(ATCC) and HUVE cells from PromoCell (Heidelberg, Germany).
The cell culture media DMEM and HUVEC growth medium were
from Gibco, Paisley, UK. Peritoneal macrophages were freshly
isolated from Sv129 mice. Female Sv129 mice and CD1 nude mice
were from Charles River Wiga (Sulzfeld, Germany) and kept in
standard housing and normal diet at the animal facility of the Paul
Scherrer Institute. Animal studies were approved by the Veterinary
Department of the Canton Aargau, Switzerland and performed
under the licenses (No. 75533 and 75534) issued to RA
Schwendener. The ethical guidelines that were followed meet the
standards required by the UKCCCR guidelines (Workman et al,
1998).
Clodronate liposomes
Clodronate liposomes, termed clodrolip, were essentially prepared
as described before (Seiler et al, 1997). Briefly, for the preparation
of 40ml of clodronate liposomes, the following composition was
used. Soy phosphatidylcholine (4.0g, Epikuron 200, Lukas Meyer,
Hamburg, Germany), cholesterol (0.6g, Fluka, Buchs, Switzerland)
and D,L-a-tocopherol (0.02g, Merck, Darmstadt, Germany) corre-
sponding to 1:0.3:0.01mol parts were prepared by freeze–
thawing and filter extrusion. The dry lipid mixture was solubilised
in a physiologic phosphate buffer (20mM, pH 7.4) supplemented
with mannitol (230mM) and 2.64g clodronate (clodronic acid
disodium salt tetrahydrate, CH2Cl2Na2O6P2 4H 2O, Bioindustria
LIM, Novi Ligure, Italy). The resulting multilamellar vesicles were
freeze–thawed in three cycles of liquid nitrogen and water at 401C,
followed by repetitive (5–10 ) filter extrusion through 400nm
membranes (Nuclepore, Sterico, Dietikon, Switzerland) using a
Lipext extruder (Lipex Biomembranes, Inc., Vancouver, Canada).
Nonencapsulated clodronate was removed by dialysis (Spectrapore
tube, 12–14000mol.wt. cutoff). Liposome size and homogeneity
were routinely measured with a Nicomp laser light scattering
particle sizer (Nicomp 370, Sta. Barbara, CA, USA). Routinely
prepared small unilamellar clodrolip liposomes contain approxi-
mately 20mg clodronateml
 1 and have a mean diameter of 135 7
55nm.
Cytotoxicity assay
The in vitro cytotoxicity of clodronate was assessed as described
before (Marty et al, 2004). Briefly, cells were incubated in 96-well
plates with liposomes, clodronate and clodrolip (6h, 371C, 1mg
clodronateml
 1) and cell viability was determined by addition of
WST-1 reagent (Roche Diagnostics, Mannheim, Germany) accord-
ing to the manufacturer’s recommendations.
Tumour models and therapies
Exponentially growing F9 teratocarcinoma (7 10
650ml
 1)o r
A673 rhabdomyosarcoma cells (6–8 10
650ml
 1 mixed 1:1, vv
 1
with Matrigel, Beckton Dickinson, Basel, Switzerland) were
injected subcoutanously (s.c.) on the flanks of mice. Treatment
was started 6h after inoculation of F9 cells (female Sv129 mice)
and 24h after inoculation of A673 cells (female CD-1 nude mice),
respectively. The mice (6–8/group) received clodronate dissolved
in phosphate buffer (PB, 67mM, pH 7.4) or clodrolip by
intraperitoneal (i.p.) injection as initial dose of 2mg20g
 1 mouse
body weight, followed by 1mg for the subsequent doses. The Abs
were given at 0.5mg20g
 1 mouse body weight in 100mlP Bb y
intravenous (i.v.) injection into the tail vein. Tumour growth was
measured in a blinded fashion with a caliper and volumes were
calculated using the equation: V¼pab
2/6 (a¼largest tumour
diameter, b¼perpendicular diameter). Relative percentual tumour
growth was normalised to day one. Mice were killed 8–22 days
after onset of treatment and tumours and spleens removed for
histology.
Immunohistochemistry
Histological and immunohistochemical (IHC) assays were carried
out as described previously (Mrkic et al, 2000). Briefly, tissue
specimens for IHC analysis were collected and snap frozen. For
staining of cell differentiation markers, the following primary rat
or rabbit anti-mouse mAbs were used: CD11b (M1/70), CD11c
(HL3), CD31 (PECAM-1), FDC (rat-anti-mouse FDC), B220 (RA3–
6B2, all PharMingen, San Diego, CA, USA), CD68 (rat-anti-mouse
CD68, Serotec), F4/80 (A3–1, ATCC), CD3 (KT3, ATTC), MOMA1
and ER-TR9 (BMA Biomedicals, Augst, Switzerland) and LYVE-1
(ReliaTech, Braunschweig, Germany). Primary Abs were detected
by sequential incubation with alkaline phosphatase-labelled
species-specific secondary Abs. Alkaline phosphatase was visua-
lised using naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic
acid-2-methoxy anilide) phosphate and new fuchsin as a substrate,
yielding a red reaction product. Cell nuclei were counterstained
with hemalum.
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sAnti-VEGF antibodies
Recombinant cfVEGF164 (Canis familiaris) and VEGF-E (originat-
ing from the orf-family of pox viruses) were produced in Pichia
pastoris and purified by affinity chromatography as described
previously (Scheidegger et al, 1999). Recombinant hVEGF165 was
kindly provided by A Zisch (Institute of Obstetrics, University
Hospital Zu ¨rich, Switzerland). Recombinant mVEGF164 (purity
495%) was from ReliaTech. The synthetic ETH-2 human scFv
antibody phage library was from D Neri (Institute of Pharmaceu-
tical Sciences, ETH Zu ¨rich, Switzerland) (Pini et al, 1998). For the
selection of species crossreactive scFv Abs from the phage library,
three rounds of panning with recombinant mVEGF164 and
hVEGF165 were performed. Immunotubes (Maxisorp, Nunc) were
coated with 25mgml
 1 mVEGF164 in PB (first and second panning)
followed by hVEGF165 (third panning) for 12h at room
temperature. Selected scFv antibodies were screened by ELISA
for binding to recombinant hVEGF165 and mVEGF164 using the M2
anti-FLAG-antibody (Sigma, Buchs, Switzerland) for detection.
The formation of (scFv0)2 Ab dimers was accomplished by
introduction of C-terminal cysteines as described (Marty et al,
2002). After subcloning into the yeast expression vector pPICZaA,
the selected homodimeric Abs (SZH9, V65) (Vitaliti et al, 2000)
and the unspecific control Ab A1 were produced and purified as
described (Marty et al, 2002). Binding constants against mVEGF164
and cfVEGF164 of SZH9 were determined with a competitive ELISA
assay (Friguet et al, 1985). For the determination of pharmaco-
kinetic parameters, SZH9 was iodinated (
125I) using the Iodogen
method. Female CD1 nude mice bearing subcutaneously implanted
A673 cells (6–8 10
6) at each flank were injected with 3mg
(1.85 10
5MBq) scFv Abs in 0.1ml phosphate buffer (PB, 67mM,
pH 7.4). Mice (three/group) were killed at 0.17, 0.5, 1, 2, 4, 6 and
24h after injection. Antibody concentrations in blood, liver,
kidneys and tumours were determined and expressed as percent
of injected dose per gram tissue (%IDg
 1). Pharmacokinetic
parameters were calculated with GraphPad Prism 4 software.
Statistical analysis
All measurements are shown as average7s.e.m. Statistical analysis
of data from growth inhibition experiments was performed using
a two-tailed, unpaired t-test. All P-values were calculated vs
PB controls unless indicated otherwise. P-values of o0.05 were
considered as statistically significant. The quantification of the
IHC data was performed with the image analysis software analySIS
(Soft Imaging System, Mu ¨nster, Germany).
RESULTS
Selective cytotoxicity of clodrolip
We first tested the cytotoxicity of clodronate and clodrolip on
freshly isolated murine peritoneal macrophages, human umbilical
vein endothelial cells (HUVEC), murine F9 teratocarcinoma and
human A637 rhabdomyosarcoma cells in vitro. Treatment with
clodrolip killed peritoneal macrophages in a concentration-
dependent manner resulting in an IC50 of 2.8mM or 1mgml
 1
(Figure 1A). HUVEC, F9 or A673 cells were not affected upon
incubation with clodrolip at the IC50 (Figure 1B).
Immunohistochemical analysis of spleens of Sv129 mice
(Figure 1C) showed that clodrolip treatment caused selective
depletion of activated F4/80
þ red pulp, MOMA1
þ metallophilic
marginal zone, ER-TR 9
þ marginal zone and CD11b
þ macro-
phages. CD68
þ macrophages were not depleted, but clodrolip
treatment caused clustering of CD68
þ cells (see Supplementary
Figure s1A, B). The FDC
þ and CD11c
þ dendritic myeloid cell
subsets and the B220
þ B- and CD3
þ T cells were not affected.
Clodronate did not cause any histologically visible depletion of the
analysed cell populations in the spleen (Figure 1C and Supple-
mentary Figure s1A, B).
Clodrolip promotes macrophage depletion and inhibits
tumour growth
We next studied the effects of clodrolip on tumour progression
and angiogenesis in the highly vascularised and fast-growing
syngeneic F9 teratocarcinoma mouse tumour model. Mice were
treated i.p. with PB, empty liposomes, clodronate or clodrolip. The
initial clodronate dose was 2mg20g
 1 mouse body weight,
followed by 1mg20g
 1 mouse body weight given every 4 days.
Therapy onset was 6h after tumour cell inoculation. In two groups,
clodrolip therapy was delayed to days 4 and 8, respectively.
Clodrolip treatment inhibited tumour growth, even at the most
delayed therapy onset (days 8 and 12) (Figure 2A and Supple-
mentary Figure s2A). The most effective growth inhibition (74%,
P¼0.0185) was obtained with an early treatment on days 0, 4, 8
and 12. Clodronate (5mg) given on days 0, 4, 8, 12 had an
insignificant inhibitory effect of 45% (P¼0.21), comparable to the
days 4, 8 and 12 delayed clodrolip schedule (49%, P¼0.167). The
delayed onset of therapy at time points where tumours were
already established and well vascularised (day 4 or 8) resulted in
less pronounced growth inhibition, suggesting that macrophage
depletion in large tumours is not sufficient to efficiently inhibit
tumour growth.
To further elucidate the effect of clodronate on TAM depletion,
we performed a therapy experiment in the less aggressively
growing human A673 rhabdomyosarcoma xenograft model.
Clodronate was applied with two dosage schemes, high dose
(HD, 5mg total dose) and low dose (LD, 2.5mg total dose). As
shown in Figure 2B (and in Supplementary Figure s2B), the most
effective growth inhibition (66%, P¼0.028) was obtained with HD
clodrolip application, whereas clodronate HD therapy was less
active (29%, P¼0.146). Interestingly, clodrolip plus clodronate
combination therapy (LDþLD) was equally active (42%,
P¼0.027) as clodrolip LD alone (38%, P¼0.062), suggesting that
clodronate LD was ineffective. Quantification of macrophage
depletion and blood vessel density by immunohistochemistry in
A673 tumours revealed a superior, but dose-dependent depletion
by clodrolip compared with clodronate therapy. To assess the
depletion effects, four to five tumour sections from individual mice
per treatment group were analysed by determining positively
stained areas (pixel counts transformed to percent) in three
defined regions of interest of identical size. As shown on the bar
graph in Figure 2C, MOMA-1
þ macrophages are more susceptible
to clodrolip than the quantitatively larger population of the F4/
80
þ TAMs. Clodrolip was also more efficient in reducing CD31
þ
EC counts than clodronate (clodrolip HD or LD vs clodronate HD;
Po0.0003). Clodrolip treatment did not cause overt toxic side
effects in the F9 and the A673 mouse tumour model and we assume
that the spleen is repopulated with macrophages after the end of
therapy within 1–3 weeks. Likewise, the tumour stroma may be
repopulated from the periphery within the same time frame.
Compared to PB-treated control mice, treatment with a total dose
of 5mg of either clodronate or clodrolip did not significantly
change body weight (o75%) during the monitored time periods
(see Supplementary Figure s3A, B). This suggests that treatment
with clodronate produced no general toxic side effects in the mice.
Combining clodrolip treatment with VEGF neutralisation
further enhances TAM depletion and shows improved
tumour inhibition
Recognising that clodrolip-mediated depletion of TAMs might not
be effective enough for complete suppression of tumour growth,
we combined clodrolip with an antiangiogenic therapy by systemic
application of anti-VEGF antibodies. In the F9 model, mice were
Clodronate-liposome-mediated TAM depletion
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seither treated with PB, an unspecific control antibody A1, with
the anti-mVEGF Ab V65 (Vitaliti et al, 2000) or with antibody
combined with clodrolip. Clodrolip therapy was started 6h after
tumour cell inoculation, followed by additional applications on
days 6 and 11 (Figure 3A). Clodrolip-mediated TAM depletion
decreased tumour volumes (Figure 3B) significantly by 82%
(P¼0.003). Blocking VEGF with V65 antibody reduced tumour
volumes by 65% (P¼0.047). The combination protocol resulted in
a significantly higher reduction of 92% (P¼0.001), corresponding
to 10 and 28% higher values compared to the single treatments,
respectively.
Encouraged by the results obtained with V65, we reasoned that
a VEGF-blocking antibody that neutralises both tumour cell-
secreted human VEGF and mouse VEGF expressed by stromal host
cells, such as macrophages, ECs and fibroblasts, would be
advantageous to prevent the growth of xenograft tumours. Thus,
we generated a mouse–human crossreactive anti-VEGF scFv
recombinant antibody SZH9 and functionalised it at its carboxy
terminus to allow further derivatisation and dimerisation (Marty
et al, 2002).
To evaluate whether SZH9 would neutralise VEGF and conse-
quently block angiogenesis in vivo, we used the chick chorioal-
lantois membrane assay (CAM) (Scheidegger et al, 1999). Vascular
endothelial growth factor-induced angiogenesis was reproducibly
inhibited by coincubation with SZH9. Compared to the control
antibody A1, vessel sprouting induced by VEGF164 was inhibited
by SZH9 (see Supplementary Figure s4A). Additionally, pharma-
cokinetic properties of SZH9 were assessed in a biodistribution
experiment in A673 tumour-bearing mice (see Supplementary
Figure s4B). Radio-iodinated SZH9 was rapidly eliminated from
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 1 clodronate or clodrolip for 6h. Results are means7s.e.m. (n¼3). Statistical analysis:
*Po0.05 vs untreated cells. (C) Selective depletion of spleen cell populations after treatment with clodronate and clodrolip. Spleen tissues obtained from
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every 4 days, i.p.). Spleens were removed and sections IHC stained for marginal zone metallophilic MOMA1
þ, marginal zone ER-TR 9
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sblood with a biphasic profile resulting in a blood distribution half-
life of t1/2a¼0.2h and an elimination half-life of t1/2b¼3.3h. A
peak accumulation level of approximately 3% of the injected dose
was reached in the tumour 4h after application. Unlike IgG
antibodies, SZH9 did not accumulate to significant levels in the
liver or other organs. Further properties of the SZH9 antibody are
summarised in the Supplementary Figure s5A–C and s5D–G.
The superior tumour inhibitory effect of combined clodrolip/
antibody therapy was confirmed in the A673 tumour model
(Figure 3C). The antibodies SZH9 or A1 were given in combination
with clodrolip on days 5–13 every 24h. Clodrolip treatment
decreased tumour volumes by 63% (P¼0.015) and treatment with
SZH9 by 59% (P¼0.04). The combination therapy was again
clearly better than the single treatments resulting in growth
inhibition by 74% (P¼0.009; Figure 3D; left panel, day 16). In both
tumour models, the combination therapy resulted in drastic
tumour growth inhibition with nearly complete suppression in the
strongly VEGF-dependent A673 model that persisted up to 9 days
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**P¼0.01. MOMA1, clodrolip HD and LD, ***Po0.0001; clodronate HD, ***P¼0.0005; clodronate LD, **P¼0.0014 and combination LDþLD,
***Po0.0001. CD31, clodrolip HD and LD, ***Po 0.0002, clodronate HD and LD and combination LDþLD, NS and clodrolip HD or LD vs clodronate
HD, ***Po0.0003.
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Figure 3 Combination of clodrolip treatment with VEGF neutralisation further enhances TAM depletion and shows improved tumour inhibition in the
syngeneic F9 teratocarcinoma (A, B) and in the xenogenic human A673 rhabdomyosarcoma (C, D) models. (A) Tumour growth inhibition by clodrolip
treatment in combination with the anti-mVEGF Ab V65. F9 tumour-bearing mice (3–5group
 1) were treated with PB, control Ab A1, V65, clodrolip plus
A1 or clodrolip plus V65. Each clodrolip dose contained initially 2mg20g
 1 mouse body weight (day 0, i.p.), followed by 1mg (days 6 and 11, i.p) and the
Abs were given at 0.5mg (days 3–7 and 10, i.v.). Values represent the mean of treated mice7s.e.m. (n¼3–5). Relative percentual tumour growth was
normalised to day 1. (B) Bar graph of tumour volumes measured on day 14, showing the calculated averages7s.e.m. (n¼3–5). Statistical analysis: *Po0.05;
V65 vs clodrolipþV65, P¼0.0118 and clodrolipþA1 vs clodrolipþV65, P¼0.014. (C) Tumour growth inhibition by the combination treatment in A673
rhabdomyosarcomas. Tumour-bearing mice (6–8/group) were treated with PB, control Ab A1, SZH9 Ab (days 5–13, i.v.), clodrolip plus A1 or clodrolip
plus SZH9 (days 1, 5, 9 and 13, i.p.) as in (A). Values represent the mean of treated mice7s.e.m. (n¼6–8). (D) Bar graph of tumour growth inhibition
measured at days 16 (open bars) and 22 (grey bars) showing the tumour volumes as calculated averages7s.e.m. Statistical analysis: individual P-values for day
16, *P¼0.039, **P¼0.015, ***P¼0.009; for day 22, *P¼0.026, **P¼0.007, ***P¼0.0002; NS, not significant. VEGF-neutralising properties and
pharmacokinetic data of SZH9 are shown in Supplementary Figures s4 and s5.
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safter ending treatment (as shown in Figure 3C and D; right panel,
day 22).
Immunohistochemical analysis of TAM depletion
Immunohistochemical analysis of A673 tumour sections from mice
killed 3 and 9 days, respectively, after ending treatment was
performed to evaluate macrophage inflitration and vessel density
in the tumour mass (days 16 and 22, see Figure 3C and D).
Substantial depletion of tumour-associated F4/80
þ and MOMA1
þ
macrophages was observed 3 days after the last clodrolip
application (Figure 4A) that persisted up to the end of the
experiment (Figure 4B). Immunohistochemical analysis of tumour
sections for CD11b
þ TAMs and CD11c
þ TADCs gave unexpected
results. Whereas both cell populations remained unaffected in the
spleen (see Figure 1B and Supplementary Figure s1), treatment of
A673 tumours with SZH9, clodrolip or with a combination of
both reagents strongly reduced the CD11b
þ cell population,
C
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Figure 4 Immunohistochemical analysis of TAM depletion and correlation to blood vessel density. (A) A673 tumour sections obtained from mice
injected with PB, A1, SZH9, clodrolip alone or in combination with SZH9 on days 16 after onset of treatment were analysed by IHC. Depletion of activated
F4/80
þ, marginal zone MOMA1
þ and CD11b
þ TAMs and of CD11c
þ tumour-associated dendritic cells (TADCs) is shown. Blood vessel staining is
shown by staining of CD31
þ endothelial cells. Arrows show cells that were not depleted (or repopulated) after the end of therapy. Bars: 100mm. (B)
Quantification of F4/80
þ, MOMA1
þ, CD11b
þ TAMs, CD11c
þ TADCs and CD31
þ ECs (blood vessels) at day 22 (see Figure 3C and D). Three to five
tumour sections were stained and quantified as indicated in Figure 2C. The bars show the calculated averages7s.e.m. (n¼9–15) in percents referred to the
PB control sections. Statistical analysis: *Po0.05; **Po0.01 and ***Po0.001. Individual P-values: F4/80, SZH9, NS; clodrolip, **P¼0.0003;
clodrolipþSZH9, ***Po0.0001. MOMA1, SZH9, *P¼0.043; clodrolip, ***P¼0.0001; clodrolipþSZH9, ***Po0.0001. CD31, SZH9, *P¼0.03;
clodrolip, ***Po0.0001; clodrolipþSZH9, ***Po0.0001. CD11b, SZH9, NS; clodrolip, P¼0.033; clodrolipþSZH9, *P¼0.03. CD11c, SZH9, *P¼0.019;
clodrolip, **P¼0.0055 and clodrolipþSZH9, **P¼0.0002. (C) Correlation of TAM depletion (F4/80
þ, MOMA-1
þ, CD11b
þ) and of CD11c
þ TADCs
vs vessel density (CD31
þ cells). The dots represent values of positively stained areas from individual tumours, showing the clear separation of clodrolip
treated (box) compared to other groups (PB, Ab A1, Ab SZH9). Statistical analysis (Pearson correlation, n¼20): F4/80, r¼0.701, P¼0.0006; MOMA1,
r¼0.711, P¼0.0004; CD11b, r¼0.50, P¼0.025; CD11c, r¼0.531, P¼0.016.
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swhereas CD11c
þ TADCs were completely eradicated (Figure 4A
and B).
To assess the effect of these treatments on tumour vascularisa-
tion, we analysed vessel density by CD31
þ staining. At 3 days after
the end of therapy (day 16), tumour blood vessels were virtually
undetectable and significant reduction in vessel density was
observed even 9 days later (Figure 4A and B).
Quantification and statistical analysis of the IHC results from
A673 tumour sections of individual mice showed depletion of
tumour-associated F4/80
þ by 93% (P¼0.0003) and of MOMA1
þ
macrophages by 90% (P¼0.0001) in clodrolip-treated animals.
Interestingly, even single treatment with SZH9 resulted in
depletion of F4/80
þ by 52% (P¼0.18) and of MOMA1
þ
macrophages by 30% (P¼0.043, Figure 4B). We explain this effect
by the inhibition of VEGF acting as an attractant for macrophages.
The combination therapy was not significantly superior over
the single treatments with respect to F4/80
þ and MOMA1
þ
macrophage depletion, presumably owing to the almost quantita-
tive depletion obtained with clodrolip alone (Figure 4A and B).
CD11b
þ TAMs were reduced by 24% (P¼0.114) after SZH9, by
59% (P¼0.033) after clodrolip and by 74% (P¼0.029) after
clodrolip plus SZH9 treatment, respectively (Figure 4A and B).
Finally, significant depletion of CD11c
þ TADCs by 96%
(P¼0.043) after SZH9, by 99% (P¼0.0034) after clodrolip and
by 99% (P¼0.0006) after clodrolip plus SZH9 treatment,
respectively, was observed (Figure 4A and B).
Quantification of CD31
þ ECs on day 22 showed that SZH9
monotherapy reduced vessel density by 48% (P¼0.03), clodrolip
alone by 89% (Po0.0001), whereas the combination therapy gave
an 85% (Po0.0001) reduction which was statistically not
significantly different from clodrolip monotherapy (Figure 4B).
The correlation of F4/80
þ and MOMA1
þ macrophage density vs
microvessel counts (CD31
þ cells) showed a clear separation of
tumours treated with clodrolip or clodrolip plus SZH9 compared
to tumours treated with SZH9 alone or with A1 or PB. (Figure 4C;
top). Correlation of CD11b
þ and CD11c
þ cell depletion with
vessel density (CD31
þ cells) confirms these results (Figure 4C;
bottom panel). CD11c
þ TADCs, which are partially also CD11b
þ,
can differentiate into endothelial-like cells in a VEGF-dependent
fashion as shown before (Coukos et al, 2005). Thus, blocking VEGF
and, at the same time, depleting TAMs significantly reduced
TADCs and this presumably resulted in the drastic reduction of
vessel density observed in tumour sections. A summary of the
quantification of these data in A673 tumours with all IHC markers
used is given in Table 1.
DISCUSSION
Tumour-associated macrophages are derived from circulating
monocytes and are activated macrophages of the polarised type
II (type II or M2 macrophages) induced by IL-4, IL-13 (M2a) or IL-
10 (M2c) and glucocorticoid hormones. Differential cytokine and
chemokine production and coordinated temporal and spatial
activities of these cells in the tumour stroma are key features of
polarised macrophages and promote tumour angiogenesis and
growth (Mantovani et al, 2004). Owing to their tumour stimulatory
role, TAMs have been proposed as potential therapeutic targets
(Joyce, 2005). However, direct elimination of these macrophages
has not yet been exploited in a drug-based therapeutic approach.
In this study, we evaluated the technique of macrophage depletion
using clodronate encapsulated in small unilamellar liposomes
(clodrolip) as potential therapeutic regimen. We show that this
approach, combined with scFv antibody-mediated neutralisation
of VEGF, leads to virtually complete elimination of F4/80
þ and
MOMA1
þ TAMs and CD11c
þ TADCs. TAM depletion was
accompanied by significant inhibition of tumour growth in both
syn- and xenogenic tumour models. From these data, we surmise
that TAM depletion is indeed the cause of tumour growth
inhibition. Depleting these stromal cell subsets presumably
disrupts the cytokine network owing to an imbalance in the cell
populations that are the source of tumour stimulatory chemokines
and cytokines.
In our experiments, antiangiogenic combination therapy was
successful, yet it was not able to fully suppress tumour growth,
resulting in slow regrowth of tumours after the end of therapy.
Depleting TAM and CD11c
þ TADC subsets apparently did not
exhaust all stromal sources of proangiogenic and tumourigenic
mediators, such as for example mast cells, neutrophils, fibroblasts
and other DC subsets, and possibly also pericytes. Thus, TAM
depletion, as most antiangiogenic therapies, ought to be regarded
as an adjuvant treatment in combination with conventional
chemo- or radiotherapy. Low-dose clodrolip therapy applied at
higher frequency, also termed ‘metronomic’ therapy (Kerbel and
Kamen, 2004), might be superior to conventional maximal
tolerated dose regimens and further improve TAM and TADC
depletion. In addition, such low-dose regimens, while still keeping
the levels of TAMs low, might reduce systemic immunosuppressive
effects. Additional suppression of systemic side effects might be
achieved by specific targeting of clodronate-liposomes to TAMs,
using for example mannosylated liposomes targeted to M2
polarised macrophages that express high levels of the mannose
receptor. Alternatively, clodronate-containing liposomes could be
conjugated with anti-ED-B fibronectin antibodies for selective
deposition of TAM-depleting liposomes in the tumour matrix
(Marty et al, 2002).
The important role of VEGF was further supported by the
distinct antiangiogenic effect obtained with the anti-VEGF anti-
body monotherapy, which resulted in a reduction of F4/80
þ,
MOMA
þ and CD11b
þ TAMs and the eradication of CD11c
þ
TADCs. This implies that, due to a decrease in the number of
blood vessels, macrophage and DC infiltration into the stroma is
reduced, or that blocking VEGF prevents monocyte attraction, or,
most likely, that both mechanisms simulatenously influence TAM
accumulation in tumours. High VEGF, IL-6, IL-10, TGFb and
M-CSF levels in the tumour microenvironment block dendritic
cell differentiation and maturation. Whereas functionally mature
myeloid dendritic cells induce potent tumour-associated antigen-
specific immunity in vivo, immature myeloid cells (IMCs) either
suppress regulatory T cells (Treg) or lead to T-cell unresponsive-
ness (Zou, 2005). Immature myeloid cells function as regulatory
cells and are therefore an important component of the immuno-
suppressive networks in the tumour microenvironment. Recent
findings demonstrate that IMCs in the spleen of tumour-bearing
mice differentiate towards F4/80
þ TAMs. These TAMs are able to
Table 1 Summary of IHC analysis
Treatment and histological scoring of A673 tumors
Marker PBS A1 SZH9 Clodrolip Clodrolip+SZH9
F4/80 +++ +++ ++   
MOMA1 +++ +++ ++   
ER-TR 9         
CD68
a +++ +++ +++ +++ +++
CD11b +++ +++ ++ ++ ++
CD11c +++ +++     
CD31 +++ +++ ++ + +
LYVE-1         
aFor IHC sections, see Supplementary Figure s4. Scoring of TAM (F4/80, MOMA1,
ER-TR 9, CD68, CD11b), TADC (CD11c) and blood-endothelial (CD31) or lymph-
endothelial (LYVE-1) cell depletion efficiency. Depletion efficiencies in A673 tumours
with all cell markers from IHC tumour specimens are listed (day 22, experiment
shown in Figure 2B, C). Scoring of staining: +++, very strong; ++ moderate; +weak
or inconsistent,  absent. Histological sections of HE- and CD68-stained A673
tumours are shown in Supplementary Figure s6A and B.
Clodronate-liposome-mediated TAM depletion
SM Zeisberger et al
279
British Journal of Cancer (2006) 95(3), 272–281 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sinhibit a T-cell-mediated immune response controlled by STAT1
(Kusmartsev and Gabrilovich, 2005). Moreover, the in vivo
ablation of CD11c
þ dendritic cells in diphtheria-toxin transgenic
mice abrogates priming of cytotoxic T-lymphocyte precursors in
immune responses to cell-associated antigens, a phenomenon
called cross-priming (Jung et al, 2002). The complexity of DC
populations and their different functions in the tumour micro-
environment is accentuated by the recent discovery of a
population of CD11c
þ DCs, termed vascular leucocytes. These
DCs simultaneously express both endothelial and dendritic cell
markers, and, depending on the microenvironment, assemble into
functional blood vessels or act as antigen-presenting cells.
Dendritic cell precursor-mediated vasculogenesis has also been
found to be regulated through the cooperation of b-defensins and
VEGF-A, where VEGF-A primarily induces their endothelial-like
specialisation and migration to blood vessels (Coukos et al, 2005).
Thus, removal of an important source of VEGF and concomitant
blocking of VEGF with neutralising antibodies, as implemented
in our therapeutic regimen, might be the major cause for the
disappearance of this DC subpopulation. Chemokines and
chemokine receptors have been used as targets for the develop-
ment of therapeutic strategies to control inflammatory disorders,
and recent results suggest that chemokine inhibitors also affect
tumour growth by reducing macrophage infiltration (Balkwill,
2004). Colony stimulating factor 1 (CSF-1), a cytokine commonly
produced by tumours, triggers monocyte migration (Pixley and
Stanley, 2004) and blocking CSF-1 or its receptor has been shown
to suppress macrophage infiltration and to reduce tumour growth
(Aharinejad et al, 2004).
Recently, it was shown by Allavena et al (2005) that Yondelis
(Trabectedin), a new anticancer agent of marine origin, markedly
reduced the levels of proinflammatory cytokines CCL2 and IL-6 in
monocytes and macrophages, thus inhibiting macrophage viabi-
lity, differentiation and cytokine production.
Finally, VEGF-C production by TAMs was proposed to play a
role in lymphangiogenesis and lymphatic metastasis in several
human cancers (Pepper et al, 2003).
Taken together, our findings provide solid evidence for the
importance of TAMs, and possibly also of TADCs, in the
establishment of a microenvironment favouring tumour growth
and dissemination. Clodronate- or other bisphosphonate lipo-
some-mediated macrophage depletion regimens open new possi-
bilities to study the role of tumour infiltrating cells, for example
by gene expression profiling of TAM-depleted tumours. In
addition, TAM depletion combined with new antiangiogenic or
cytotoxic therapies is a promising new approach with high clinical
potential.
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